P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 284-292

  Shapira, Iuliana ^a   Lee, Annette ^a   Vora, Reena ^a   Budman, Daniel R ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Basal like breast cancer; EGFR; Endosomal trafficking; Integrin; P53 mutation; P63; Triple negative breast cancer

Indexed keywords

AFATINIB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CLATHRIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; INTEGRIN; IRINOTECAN; IXABEPILONE; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN P53; PROTEIN P63;

CANCER CHEMOTHERAPY; CELL MEMBRANE; ENDOCYTOSIS; ENDOSOME; GAIN OF FUNCTION MUTATION; GENE MUTATION; HUMAN; INFLAMMATORY BREAST CANCER; INTERNALIZATION; LOADING DRUG DOSE; METASTASIS POTENTIAL; MISSENSE MUTATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN TRANSPORT; REVIEW; SKIN TOXICITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION;

BASAL LIKE BREAST CANCER; EGFR; ENDOSOMAL TRAFFICKING; INTEGRIN; P53 MUTATION; P63; TRIPLE NEGATIVE BREAST CANCER;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ENDOSOMES; FEMALE; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885860445     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.003     Document Type: Review

References (97)

1. Davies C., Godwin J., Gray R., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784.
2. Loi S., de Azambuja E., Pugliano L., et al. HER2-overexpressing breast cancer: time for the cure with less chemotherapy?. Current Opinion in Oncology 2011, 23(6):547-558.
3. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52(1):108-118.
4. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378(9805):1812-1823.
5. Fumagalli D., Andre F., Piccart-Gebhart M.J., et al. Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?. Critical Reviews in Oncology/Hematology 2012.
6. Rakha E.A., El-Sayed M.E., Green A.R., et al. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32.
7. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 2011, 121(7):2750-2767.
8. Cavallaro S., Paratore S., de Snoo F., et al. Genomic analysis: toward a new approach in breast cancer management. Crit Rev Oncol Hematol 2012, 81(3):207-223.
9. Comprehensive molecular portraits of human breast tumours. Nature 2011, 490(7418):61-70.
10. Ma C.X., Luo J., Ellis M.J. Molecular profiling of triple negative breast cancer. Breast Disease 2010, 32(1-2):73-84.
11. Stefansson O.A. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 2011, 6(5):638-649.
12. Catteau A., Harris W.H., Xu C.F., et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 1999, 18(11):1957-1965.
13. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. Journal of the National Cancer Institute 2000, 92(7):564-569.
14. Manie E., Vincent-Salomon A. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Research 2009, 69(2):663-671.
15. Holstege H., Joosse S.A., van Oostrom C.T., et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Research 2009, 69(8):3625-3633.
16. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
17. Tabaries S., Dong Z., Annis M.G., et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2010, 30(11):1318-1328.
18. Toyama T., Yamashita H., Kondo N., et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 2008, 8:p309.
19. Lerma E., Peiro G., Ramon T., et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Modern Pathology 2007, 20(11):1200-1207.
20. Viale G., Rotmensz N., Maisonneuve P., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment 2009, 116(2):317-328.
21. Bhargava R., Gerald W.L., Li A.R., et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Modern Pathology 2005, 18(8):1027-1033.
22. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(19):10869-10874.
23. Wilhelmsen K., Litjens S.H., Sonnenberg A. Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis. Molecular and Cellular Biology 2006, 26(8):2877-2886.
24. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nature Medicine 2004, 10(8):789-799.
25. Wiley H.S. Trafficking of the ErbB receptors and its influence on signaling. Experimental Cell Research 2003, 284(1):78-88.
26. Higashiyama S., Iwabuki H., Morimoto C., et al. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 2008, 99(2):214-220.
27. Luetteke N.C., Qiu T.H., Fenton S.E., et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126(12):2739-2750.
28. Lee D.C., Sunnarborg S.W., Hinkle C.L., et al. TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Annals of the New York Academy of Sciences 2003, 995:22-38.
29. Waters K.M., Liu T., Quesenberry R.D. Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphorylation data. PLoS ONE 2012, 7(3):e34515.
30. Gilmore J.L. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Research and Treatment 2008, 110(3):493-505.
31. Balbis A., Posner B.I. Compartmentalization of EGFR in cellular membranes: role of membrane rafts. Journal of Cellular Biochemistry 2010, 109(6):1103-1108.
32. Nickerson N.K., Mohammad K.S., Gilmore J.L., et al. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS ONE 2012, 7(1):e30255.
33. Masuda H., Zhang D., Bartholomeusz C., et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Research Treatment 2012.
34. van Belzen N., Verkleij A.J., Boonstra J. Visualization and quantitative analysis of epidermal growth factor (EGF) receptors at electron microscopical level. Progress in Histochemistry and Cytochemistry 1992, 26(1-4):39-48.
35. Baulida J., Kraus M.H., Alimandi M., et al. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. Journal of Biological Chemistry 1996, 271(9):5251-5257.
36. Sorkin A., Goh L.K. Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research 2008, 314(17):3093-3106.
37. Sak M.M., Breen K., Ronning S.B., et al. The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. Carcinogenesis 2012, 33(5):1031-1039.
38. Coniglio S.J., Eugenin E., Dobrenis K., et al. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Molecular Medicine 2012, 18:519-527.
39. Patsialou A., Wyckoff J., Wang Y., et al. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Research 2009, 69(24):9498-9506.
40. Riese D.J., Kim E.D., Elenius K., et al. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. Journal of Biological Chemistry 1996, 271(33):20047-20052.
41. Willmarth N.E., Ethier S.P. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. Journal of Biological Chemistry 2006, 281(49):37728-37737.
42. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer Journal 2010, 16(1):23-32.
43. Fox S.B., Smith K., Hollyer J., et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment 1994, 29(1):41-49.
44. Siziopikou K.P., Ariga R., Proussaloglou K.E., et al. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?. Breast J 2006, 12(4):360-362.
45. Grant B.D., Donaldson J.G. Pathways and mechanisms of endocytic recycling. Nature Reviews Molecular Cell Biology 2009, 10(9):597-608.
46. Kawashima N., Yoon S.J., Itoh K., et al. Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions. Journal of Biological Chemistry 2009, 284(10):6147-6155.
47. Wang X., Gu J., Ihara H., et al. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. Journal of Biological Chemistry 2006, 281(5):2572-2577.
48. Nichols B.J., Lippincott-Schwartz J. Endocytosis without clathrin coats. Trends in Cell Biology 2001, 11(10):406-412.
49. Johannes L., Lamaze C. Clathrin-dependent or not: is it still the question?. Traffic 2002, 3(7):443-451.
50. Sorkina T., Huang F., Beguinot L., et al. Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. Journal of Biological Chemistry 2002, 277(30):27433-27441.
51. Caswell P.T., Vadrevu S., Norman J.C. Integrins: masters and slaves of endocytic transport. Nature Reviews Molecular Cell Biology 2009, 10(12):843-853.
52. Subramani D., Alahari S.K. Integrin-mediated function of Rab GTPases in cancer progression. Molecular Cancer 2010, 9:312.
53. Scita G., Di Fiore P.P. The endocytic matrix. Nature 2010, 463(7280):464-473.
54. Olivier M., Langerod A., Carrieri P., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clinical Cancer Research 2006, 12(4):1157-1167.
55. Olivier M., Eeles R., Hollstein M., et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutation 2002, 19(6):607-614.
56. Selivanova G., Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26(15):2243-2254.
57. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer 2009, 9(10):701-713.
58. Ding L. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464(7291):999-1005.
59. Scaringe W.A. Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates. Human Molecular Genetics 2008, 17(18):2910-2918.
60. Lo Nigro C., Vivenza D., Monteverde M., et al. High frequency of complex TP53 mutations in CNS metastases from breast cancer. British Journal of Cancer 2011.
61. Molyneux G., Geyer F.C., Magnay F.A., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Stem Cell Stem 2010, 7(3):403-417.
62. Muller P.A., Caswell P.T., Doyle B., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139(7):1327-1341.
63. Liu G., McDonnell T.J., Montes de Oca Luna, et al. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(8):4174-4179.
64. Lang G.A., Iwakuma T., Suh Y.A., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119(6):861-872.
65. Olive K.P., Tuveson D.A., Ruhe Z.C., et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119(6):847-860.
66. Ceresa B.P., Bahr S.J. rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. Journal of Biological Chemistry 2006, 281(2):1099-1106.
67. Li Y., Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26(15):2220-2225.
68. Sakane A., Hatakeyama S., Sasaki T. Involvement of Rabring7 in EGF receptor degradation as an E3 ligase. Biochemical and Biophysical Research Communications 2007, 357(4):1058-1064.
69. Taub N., Teis D., Ebner H.L., et al. Late endosomal traffic of the epidermal growth factor receptor ensures spatial and temporal fidelity of mitogen-activated protein kinase signaling. Molecular Biology of the Cell 2007, 18(12):4698-4710.
70. Adorno M., Cordenonsi M., Montagner M., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137(1):87-98.
71. Moll U.M., Slade N. p63 and p73: roles in development and tumor formation. Molecular Cancer Research 2004, 2(7):371-386.
72. Senoo M., Pinto F., Crum C.P., et al. p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007, 129(3):523-536.
73. Candi E., Dinsdale D., Rufini A., et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 2007, 6(3):274-285.
74. Buckley N.E. The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Research 2011, 71(5):1933-1944.
75. Feng Z. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harbor Perspectives Biology 2010, 2(2):a001057.
76. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl. (1)):1-11.
77. Caswell P., Norman J. Endocytic transport of integrins during cell migration and invasion. Trends in Cell Biology 2008, 18(6):257-263.
78. Liao H.J., Carpenter G. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Research 2009, 69(15):6179-6183.
79. Mettlen M., Stoeber M., Loerke D., et al. Endocytic accessory proteins are functionally distinguished by their differential effects on the maturation of clathrin-coated pits. Molecular Biology of the Cell 2009, 20(14):3251-3260.
80. von Kleist L., Stahlschmidt W., Bulut H., et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 2011, 146(3):471-484.
81. Dutta D., Williamson C.D., Cole N.B., et al. Pitstop 2 is a potent inhibitor of clathrin-independent endocytosis. PLoS ONE 2012, 7(9):e45799.
82. Guida E., Bisso A., Fenollar-Ferrer C., et al. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Research 2008, 68(16):6550-6558.
83. Freed-Pastor W.A., Mizuno H., Zhao X., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148(1-2):244-258.
84. Modi S., D'Andrea G., Norton L., et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical Breast Cancer 2006, 7(3):270-277.
85. Baselga J., Steemer S., Pego A., et al. Cetuximab+Cisplatin in estrogen receptor-negative, progesteron receptor negative, Her2-negative (triple negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Research 2010, 70(24 (Suppl)). p. SABCS10-PD01-01.
86. Rivera P., Filleron T., Gladieff L., et al. Efficacy of cetuximab plus platinum agent in advanced, triple negative breast carcinoma: Results of a retrospective analysis. Journal of Clinical Oncology 2011, 29(Suppl). (Abstr E11581).
87. Nabholtz J., Weber B., Mouret-Reynier M., et al. Panitumumab in combination with FEC100 (5-fluorouracil, epidoxorubicin, cyclophosphamide) followed by docetaxel (T) in patients with operable, triple negative breast cancer (TNBC): preliminary results of a multicenter neoadjuvant pilot phase II study. Journal of Clinical Oncology 2011, 29(Suppi). (abstr e11574).
88. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Preliminary results of a randomized phase II study of weekly irinotecan and carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Research and Treatment 2007, 106(supplement32). (Abstract 308).
89. Carey L.A., Rugo H.S., Marcom P.K., et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology 2012, 30(21):2615-2623.
90. Schuller M.H., Uttenreuther-Fischer M.M., Piccart-Gebhart M.J., et al. BIBW 2992, a novel irreversible EGFR/Her1 and Her2 tyrosine kinase inhibitor, for the treatment of patients with Her2 negative metastatic breast cancer after failure of no more than two prior chemotherapies. Journal of Clinical Oncology 2010, 28(Suppl). (Abstr 1065).
91. Bernsdorf M., Ingvar C., Jorgensen L., et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011, 126(2):463-470.
92. Accessed March 30, 2013. http://clinicaltrials.gov/show/NCT01097642.
93. Accessed on March 30 2013. http://www.clinicaltrials.gov/ct2/show/NCT00491816.
94. Accessed March 30, 2013. http://www.clinicaltrials.gov/ct2/show/NCT00600249.
95. Willnow T.E., Christ A., Hammes A. Endocytic receptor-mediated control of morphogen signaling. Development 2012, 139(23):4311-4319.
96. Felkl M., Tomas K., Smid M., et al. Monitoring the cytoskeletal EGF response in live gastric carcinoma cells. PLoS ONE 2012, 7(9):e45280.
97. Zeigerer A. Rab5 is necessary for the biogenesis of the endolysosomal system in vivo. Nature 2012, 485(7399):465-470.